Holen Sie sich die Stockscreener-App
1.54
4.76%
0.07
Handel nachbörslich:
1.54
Schlusskurs vom Vortag:
$1.47
Offen:
$1.46
24-Stunden-Volumen:
206.57K
Relative Volume:
0.44
Marktkapitalisierung:
$65.05M
Einnahmen:
$88.55M
Nettoeinkommen (Verlust:
$-53.21M
KGV:
-1.1902
EPS:
-1.2939
Netto-Cashflow:
$-29.48M
1W Leistung:
+10.79%
1M Leistung:
+7.69%
6M Leistung:
-24.51%
1J Leistung:
-41.89%
1-Tages-Spanne:
$1.43
$1.55
1-Wochen-Bereich:
$1.3874
$1.55
52-Wochen-Spanne:
$1.13
$3.88
Pulmonx Corp Stock (LUNG) Company Profile
Firmenname
Pulmonx Corp
Sektor
Branche
Telefon
650-364-0400
Adresse
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
1.54 | 65.05M | 88.55M | -53.21M | -29.48M | -1.2939 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | Eingeleitet | D. Boral Capital | Buy |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-04 | Eingeleitet | Lake Street | Buy |
| 2024-02-23 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | Eingeleitet | Citigroup | Buy |
| 2021-03-25 | Eingeleitet | Piper Sandler | Neutral |
| 2021-03-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-26 | Eingeleitet | BofA Securities | Buy |
| 2020-10-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-10-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-10-26 | Eingeleitet | Stifel | Buy |
| 2020-10-26 | Eingeleitet | Wells Fargo | Equal Weight |
Alle ansehen
Pulmonx Corp Aktie (LUNG) Neueste Nachrichten
Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz - Kalkine Media
Pulmonx Corp highlights lung device strategy as a specialized medtech player - ad-hoc-news.de
Enterprise value to EBITDA forward of Pulmonx Corp. – LSX:A2P1AF - TradingView
Price to earnings forward of Pulmonx Corp. – LSX:A2P1AF - TradingView
Price to sales forward of Pulmonx Corp. – DUS:4NI - TradingView
Pulmonx Corp highlights its respiratory device portfolio as investors assess long-term growth prospe - ad-hoc-news.de
LUNG News | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulmonx Corp. Actuals & Estimates (NASDAQ:LUNG) - TradingView
Pulmonx Corp (LUNG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pulmonx Corp (LUNG) Institutional Confidence - TradingKey
Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pulmonx Corp (LUNG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulmonx Corp (LUNG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonx (LUNG) awards 40,000 restricted stock units to director - Stock Titan
Director Ferrari (LUNG) awarded 40,000 Pulmonx restricted stock units - Stock Titan
Pulmonx Corp (LUNG) director granted 40,000 restricted stock units - Stock Titan
[Form 4] Pulmonx Corp Insider Trading Activity - Stock Titan
Pulmonx (LUNG) director receives 40,000-share RSU stock grant - Stock Titan
Don't Ignore The Insider Selling In Pulmonx - Sahm
Pulmonx (NASDAQ: LUNG) investors back board, auditor and executive pay - Stock Titan
Pulmonx general counsel David Lehman sells $22,474 in stock - Investing.com UK
Pulmonx general counsel David Lehman sells $22,474 in stock By Investing.com - Investing.com India
Pulmonx (LUNG) officer sells 14,497 shares to cover RSU tax withholding - Stock Titan
Pulmonx (LUNG) General Counsel sells 14,594 shares to cover RSU tax obligations - Stock Titan
Pulmonx (LUNG) CCO sells shares to cover RSU tax obligations - Stock Titan
Pulmonx (LUNG) CEO logs 56K-share sale tied to RSU tax withholding - Stock Titan
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
17 Pulmonx hires receive 84,300 RSUs in Nasdaq inducement plan - Stock Titan
Pulmonx (LUNG) Q1 2026 Earnings Transcript - AOL.com
LUNGPulmonx Corp Stock Price and Quote - Finviz
QTEX Stock Price and Chart — NASDAQ:QTEX - TradingView
Pulmonx (LUNG) Holds Steady Near $1.54 as Key Support and Resistance Levels Define Trading RangeProtective Put - The Legal Advocate
Pulmonx Corp stock (US74586W1018): Q1 2026 results highlight growth path in minimally invasive lung - AD HOC NEWS
Pulmonx Corp stock (US74586W1018): credit line and margin focus keep lung care specialist in the spo - AD HOC NEWS
LUNG Technical Analysis | Trend, Signals & Chart Patterns | PULMONX CORP (NASDAQ:LUNG) - ChartMill
TradingKey - TradingKey
Why Pulmonx Corporation (LUNG) valuation makes sense when you dig deeper (Marginal Loss) 2026-05-11Buffered ETF - Newser
Pulmonx Corporation (LUNG) beats Q1 estimates with EPS improvement despite revenue growth; shares decline as investors focus on losses.AI Trading Community - Newser
Pulmonx Corporation Q1 2026 Financial Report Highlights, Forward-Looking Statements, and Key Risk Factors - Minichart
Pulmonx (NASDAQ: LUNG) secures $40M Perceptive loan and ends Q1 with $61.6M cash - Stock Titan
Pulmonx Corp 1Q 2026: Revenue $20.59M, EPS ($0.33) — 10-Q Summary - TradingView
Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Pulmonx (NASDAQ:LUNG) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Pulmonx Corporation (NASDAQ:LUNG) Q1 2026 Earnings Call Transcript - Insider Monkey
LUNG Maintained by D. Boral Capital -- Price Target Stays at $14 - GuruFocus
Pulmonx Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Finanzdaten der Pulmonx Corp-Aktie (LUNG)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):